Brief: Kronos Bio Announces First Patient Dosed In Phase 1/2 Clinical Trial Of KB-0742, An Oral CDK9 Inhibitor Targeting MYC-Amplified Cancers
25/02/2021 14:41
Feb 25 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
CLINICAL
TRIAL OF KB-0742, AN ORAL CDK9 INHIBITOR TARGETING MYC-AMPLIFIED
CANCERS
* KRONOS BIO INC - INITIAL SAFETY, PHARMACOKINETIC AND
PHARMACODYNAMIC DATA EXPECTED IN Q4 OF 2021
Source text for Eikon: ID:nGNXbbnMbY
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems